Elevated Plasma Levels of Adropin in Heart Failure Patients

Abstract

Background Recent studies have suggested that a higher body mass index (BMI) is associated with an improved prognosis in heart failure (HF). Adropin is a recently identified protein that has been implicated in the maintenance of energy homeostasis. In the present study, we investigated plasma adropin levels in patients with HF and evaluated the relationship between the levels and the severity of HF. Methods and ResultsThe study group comprised 56 patients with HF and 20 control subjects, who were divided into 4 subgroups according to New York Heart Association (NYHA) functional classification. Plasma levels of adropin, brain natriuretic peptide (BNP) and cardiac hemodynamics were determined. Plasma adropin levels were significantly increased according to the severity of NYHA class in the patients with HF; control: 6.0 ± 0.3; NYHA functional Class II: 7.6 ± 0.4; NYHA functional Class III: 9.8 ± 0.5; NYHA functional Class IV: 12.4 ± 0.6 ng/mL (p<0.01). Similarly, plasma BNP levels were significantly increased in accordance with the NYHA class. Plasma adropin levels were correlated positively with BNP (r=0.723, p< 0.001), interleukin-6 (IL-6) (r=0.326, p=0.007) and body mass index (BMI) (r=0.295, p=0.014), and negatively with left ventricular ejection fraction (LVEF) (r=-0.710, p<0.001). Conclusion Plasma adropin levels were significantly increased according to the severity of HF, and BNP and BMI had independent impact on the plasma adropin level. These findings suggest that the augmented release of adropin may be involved in the pathogenesis of HF and further study is necessary to explain the precise role of adropin in HF.

Adropin Is a Brain Membrane-bound Protein Regulating Physical Activity via the NB-3/Notch Signaling Pathway in Mice

“…Because adropin had been proposed as a hepatocyte-secreted protein (1), it was expected that adropin could be found in the liver and blood samples. The controversial findings regarding circulating adropin (6,8,9,13) led us to reinvestigate the biochemical properties of adropin.…”

“…Correlations between circulating adropin levels and different pathophysiological states in mice and humans have been reported (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). In brief, the circulating concentration of adropin was reduced markedly in several metabolic diseases, including obesity-associated insulin resistance (1,5,11); obesity-related, nonalcoholic fatty liver disease (11); gestational diabetes mellitus (7); and endothelial dysfunction (6,8,14).…”

“…In brief, the circulating concentration of adropin was reduced markedly in several metabolic diseases, including obesity-associated insulin resistance (1,5,11); obesity-related, nonalcoholic fatty liver disease (11); gestational diabetes mellitus (7); and endothelial dysfunction (6,8,14). However, conversely, other studies found that plasma adropin levels in humans were not correlated inversely with obesity on the basis of body mass index (6,8,13) or with endothelial dysfunction (9). In addition, unlike findings in mice, plasma adropin levels in humans do not change in response to fasting and refeeding (5).…”

Irisin and Its Metabolic Effects: Review

“…15,16 FNDC5 ve PGC1α düzeylerinin oksijen hacmi (VO 2 ) düzeyinin pik yaptığı grupta en yüksek seviyede olduğu gözlen-miştir. Başka bir çalışmada, diyabetik olmayan erkeklerin oluşturduğu bir gruba 10 hafta boyunca aerobik egzersiz yaptırılmış ve egzersiz öncesi ve sonrası kan ve kas biyopsi örnekleri alınmıştır.…”

Adropin induction of lipoprotein lipase expression in tilapia hepatocytes

“…Even though the linkage between circulating adropin levels and other various pathophysiological conditions in mammals have been reported, the exact link with adropin remains elusive. Some studies showed that plasma adropin levels were linked with several metabolic diseases, including insulin resistance ) and nonalcoholic fatty liver disease (Sayin et al 2014) and endothelial dysfunction (Gozal et al 2013), whereas other studies found that plasma adropin levels were not correlated with endothelial dysfunction in humans with heart failure (Lian et al 2011) or with BMI in patients with type 2 diabetes mellitus (Topuz et al 2013). Besides, adropin may be involved in the metabolic adaptation to fasting, although these data are still controversial.…”